MedTrace Logo

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

NCT04432090 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2024-10-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes. The response of the body to low blood sugar will be measured in healthy people as a reference point.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Placebo

Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

DRUG

Study Medication (MBX-2982)

Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

OTHER

No medication for this group

This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.

Sponsors & Collaborators

  • AdventHealth Translational Research Institute

    lead OTHER

Principal Investigators

  • Richard Pratley, MD · Study Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2023-08-12
Completion
2023-08-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04432090 on ClinicalTrials.gov